Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
LOS ANGELES, Aug. 21, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against IntelliPharmaCeutics International Inc. (“IntelliPharmaCeutics” or the “Company”) (Nasdaq:IPCI) for possible violations of federal securities laws between January 14, 2016 and July 26, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired IntelliPharmaCeutics shares during the Class Period should contact the firm prior to the September 29, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, IntelliPharmaCeutics made false and/or misleading statements and/or failed to disclose: that the Company failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); that IntelliPharmaCeutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; that the Company was not submitting sufficient data to support approval of the NDA; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. When this news reached the public, shares of IntelliPharmaCeutics lowered in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was established by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
